2020
Expanding Our Understanding of Ovarian Cancer Risk: The Role of Incomplete Pregnancies
Lee AW, Rosenzweig S, Wiensch A, Group T, Ramus SJ, Menon U, Gentry-Maharaj A, Ziogas A, Anton-Culver H, Whittemore AS, Sieh W, Rothstein JH, McGuire V, Wentzensen N, Bandera EV, Qin B, Terry KL, Cramer DW, Titus L, Schildkraut JM, Berchuck A, Goode EL, Kjaer SK, Jensen A, Jordan SJ, Ness RB, Modugno F, Moysich K, Thompson PJ, Goodman MT, Carney ME, Chang-Claude J, Rossing MA, Harris HR, Doherty JA, Risch HA, Khoja L, Alimujiang A, Phung MT, Brieger K, Mukherjee B, Pharoah PDP, Wu AH, Pike MC, Webb PM, Pearce CL. Expanding Our Understanding of Ovarian Cancer Risk: The Role of Incomplete Pregnancies. Journal Of The National Cancer Institute 2020, 113: 301-308. PMID: 32766851, PMCID: PMC7936053, DOI: 10.1093/jnci/djaa099.Peer-Reviewed Original ResearchConceptsOvarian cancer riskInvasive epithelial ovarian cancerClear cell ovarian cancerIncomplete pregnanciesEpithelial ovarian cancerOvarian cancerOvarian Cancer Association ConsortiumCancer riskOdds ratioInvasive epithelial ovarian cancer casesEpithelial ovarian cancer casesHistotype-specific analysesHistotype-specific associationsOral contraceptive useInvasive ovarian cancerHistory of breastfeedingConfidence intervalsOvarian cancer casesCase-control studyOCAC studiesMajor histotypesPooled analysisInverse associationCancer casesComplete pregnancyEstrogen Plus Progestin Hormone Therapy and Ovarian Cancer: A Complicated Relationship Explored.
Lee A, Wu A, Wiensch A, Mukherjee B, Terry K, Harris H, Carney M, Jensen A, Cramer D, Berchuck A, Doherty J, Modugno F, Goodman M, Alimujiang A, Rossing M, Cushing-Haugen K, Bandera E, Thompson P, Kjaer S, Hogdall E, Webb P, Huntsman D, Moysich K, Lurie G, Ness R, Stram D, Roman L, Pike M, Pearce C. Estrogen Plus Progestin Hormone Therapy and Ovarian Cancer: A Complicated Relationship Explored. Epidemiology 2020, 31: 402-408. PMID: 32028322, PMCID: PMC7584395, DOI: 10.1097/ede.0000000000001175.Peer-Reviewed Original ResearchConceptsRisk of ovarian cancerEstrogen-progestin combined therapyEstrogen-alone therapyAssociated with increased riskOvarian cancerCombination therapyRisk of ovarian cancer overallAssociated with increased risk of ovarian cancerOvarian cancer risk factorsPopulation-based case-control studyOvarian Cancer Association ConsortiumMenopausal hormone therapy useIncreased risk of endometrial cancerOvarian cancer overallRisk of endometrial cancerCancer risk factorsHistotypes of ovarian cancerRisk factorsProgestin hormone therapyMucinous ovarian cancerOvarian cancer casesIn-person interviewsHormone therapy useOvarian cancer histotypesCase-control study
2019
A comprehensive gene–environment interaction analysis in Ovarian Cancer using genome‐wide significant common variants
Kim S, Wang M, Tyrer J, Jensen A, Wiensch A, Liu G, Lee A, Ness R, Salvatore M, Tworoger S, Whittemore A, Anton‐Culver H, Sieh W, Olson S, Berchuck A, Goode E, Goodman M, Doherty J, Chenevix‐Trench G, Rossing M, Webb P, Giles G, Terry K, Ziogas A, Fortner R, Menon U, Gayther S, Wu A, Song H, Brooks‐Wilson A, Bandera E, Cook L, Cramer D, Milne R, Winham S, Kjaer S, Modugno F, Thompson P, Chang‐Claude J, Harris H, Schildkraut J, Le N, Wentzensen N, Trabert B, Høgdall E, Huntsman D, Pike M, Pharoah P, Pearce C, Mukherjee B. A comprehensive gene–environment interaction analysis in Ovarian Cancer using genome‐wide significant common variants. International Journal Of Cancer 2019, 144: 2192-2205. PMID: 30499236, PMCID: PMC6399057, DOI: 10.1002/ijc.32029.Peer-Reviewed Original ResearchConceptsOral contraceptive pill useExcess risk due to additive interactionOvarian cancer risk factorsOral contraceptive pillsGene-environment interaction analysisCancer risk factorsGene-environment analysisOvarian cancer casesOCP useCase-control studyGenome-wide association analysisAdditive scaleCancer casesOvarian cancerOdds ratioCommon variantsDuration of OCP useRisk allelesRisk factorsGenetic variantsAdditive interactionAssociation analysisWomenFollow-upC allele